Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection

Demirbilek, Hüseyin; Alikaşifoğlu, Ayfer; Gönç, Nazlı; Özön, Alev; Kandemir, Nurgün

doi:10.1111/j.1365-2265.2011.04185.x

Cited by 22 publications

(21 citation statements)

References 22 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding of undetectable serum estradiol levels after depot GnRHa is stronger evidence for adequate pubertal suppression. We also observed that gonadotropins and estradiol responses to depot triptorelin did not change significantly along 2 years of treatment, while previous studies only performed a unique evaluation at 3 months of treatment [13,15]. …”

Section: Discussionmentioning

confidence: 56%

“…They showed great variation, from 2.5 to 6.6 IU/l. We consider our LH-3h cutoff is not strictly comparable with them because of differences in the design of the study, the sampling time and LH assays [6] and because of the use of depot leuprolide, a different GnRHa with respect to our study [13,14,15]. Even more, these previous studies have not included the assessment of E 2 -24h in order to determine that steroidogenesis is suppressed.…”

Section: Discussionmentioning

confidence: 90%

“…Some other studies found different cutoff levels for LH after depot GnRHa injection to evaluate pubertal suppression [6,13,14,15]. They showed great variation, from 2.5 to 6.6 IU/l.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty

Freire

Gryngarten²,

Ballerini³

et al. 2015

Horm Res Paediatr

View full text Add to dashboard Cite

Background: Estradiol at baseline or after a classical gonadotropin-releasing hormone test did not reflect ovarian steroidogenesis in central precocious puberty (CPP) girls. Aims: To evaluate estradiol response to depot triptorelin, both at start and during therapy to determine how active ovarian steroidogenesis is at pubertal stage and under therapy. Methods: A prospective study was performed in 43 CPP girls. Serum luteinizing hormone and follicle-stimulating hormone at 3 h (LH-3h, FSH-3h) and estradiol at 24 h (E₂-24h) after injection of depot triptorelin 3.75 mg were measured, at first dose and at 3, 6, 12, 18 and 24 months of treatment. Results: E₂-24h after depot triptorelin was >100 pg/ml after the first dose. Estradiol response (E₂-24h) fell to levels <14 pg/ml in 78 out of 82 follow-up visits along 2 years of therapy. Concomitantly, LH-3h and FSH-3h were <4.0 and <6.3 IU/l, respectively. In 4 patients with inadequate treatment, E₂-24h, LH-3h and FSH-3h rose to pubertal values similar to those observed at first dose. Conclusion: Estradiol (<14 pg/ml) assessment 24 h after depot triptorelin administration is a reliable and simple manner to confirm ovarian suppression in CPP girls during treatment.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty

Freire

Gryngarten²,

Ballerini³

et al. 2015

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…GnRHa therapy (Leuprolide acetate) was administered at 3.75 mg every 4 weeks; the dose had to be increased to 7.5 mg in three children (cases 5, 8, 10) who had a higher LH response to GnRHa of more than 2.5 IU, 90 minutes after injections. 16 Therapy was stopped in eight patients (nos. 1, 3, 5, 6, 8, 9, 10 and 11) due to advanced bone age during the last visit.…”

Section: Therapy and Follow-upmentioning

confidence: 99%

Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty

Güven¹,

Cebeci²,

Hancılı³

2014

View full text Add to dashboard Cite

OBJECTIVE: Congenital adrenal hyperplasia (CAH) can be complicated by central precocious puberty (CPP) in children, which may compromise final height. We aimed to evaluate the effect of gonadotropin-releasing hormone analog (GnRHa) therapy on growth in children with CAH. DESIGN: Twelve children with CAH were enrolled in a follow-up study. Eight patients underwent the GnRH stimulation test. GnRHa-treatment was administered at 3.75 mg every 4 weeks; the dose had to be increased to 7.5 mg in three patients. Bone age, growth velocities and body mass index of the patients were monitored during treatment. RESULTS: Median chronologic age and bone age at diagnosis were 6.8 (3.5) years and 11 (1.2) years, respectively. Median follow-up was 4.4 (4.9) years. A significant difference was found in the median ratio of bone age to chronological age between diagnosis and last visit (p=0.005) and between the beginning of GnRHa treatment and last visit (p=0.004). Median growth velocity was 4 (2.5) cm, 3.4 (5.2) cm and 5.5 (5.5) cm at the end of the first, second and third years of the therapy, respectively. Second-year growth velocity was inversely correlated with median bone age at diagnosis (rho:-0.758, p=0.004) and at the initiation of therapy (rho:-0.876, p<0.001). CONCLUSION: GnRHa therapy should be considered for augmentation of linear growth and diminishment of bone age advancement in children with CAH complicated by CPP, particularly in children who do not have extremely advanced bone age for chronological age.

show abstract

“…Given these limitations, GnRH-stimulated gonadotropin measurements are commonly used to rule out EP. However, there is a significant overlap of peak LH levels between prepubertal and early pubertal values in normal children (5,23). In studies assessing children with signs of EP, a peak LH value of ≥5 IU/L was found to have a sensitivity of only 78% in predicting subsequent pubertal progression (23).…”

Section: Discussionmentioning

confidence: 99%

Is Premature Thelarche in the First Two Years of Life Transient?

Uçar

Saka²,

Baş³

et al. 2012

Jcrpe

View full text Add to dashboard Cite

Objective: Premature thelarche (PT) refers to isolated onset of thelarche in girls younger than 8 years of age. Most cases have an onset under 2 years of age. We aimed to establish whether the onset of thelarche under 2 years of age certifies a transient clinical course, as suggested by several authors.Methods: Sixty-seven girls with an onset of PT under 2 years of age were classified as having early puberty (EP) or classical PT after one year of follow-up. Progression of pubertal findings or absolute growth velocity (GV) standard deviation score (SDS) above 1 SDS constituted the criteria for a diagnosis of EP. Results: Twenty (29.1%) girls were classified as having EP and 47 (70.1%) girls as having classical PT. Basal serum luteinizing hormone (LH; ICMA) values at a cut-off level of 0.3 IU/L were found to be a significant risk factor for having an atypical course [OR=7.8; CI (95%): 2.04– 30.4, p=0.003]. Conclusions: Onset of thelarche under 2 years of age does not assure a transient course in a remarkable proportion of girls with PT. An absolute GV value of >1 SDS or a basal LH level ≥0.3 IU/L are suggested as indicators for close follow-up. Conflict of interest:None declared.

show abstract

Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection

Cited by 22 publications

References 22 publications

Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty

Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty

Gonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty

Is Premature Thelarche in the First Two Years of Life Transient?

Contact Info

Product

Resources

About